NewsEvents

Your Yourlocation: Home > Effects of tiotropium bromide(136310-93-5) on patients with bronchial asthma who have not been controlled after standard combination therapy

Some patients with bronchial asthma in the regular inhalation of high doses of glucocorticoid and long-acting β2 receptor agonist(LABA) after repeated acute exacerbation of asthma and the existence of persistent airflow obstruction.

METHODS: (1) The study was a randomized, double-blind, placebo-controlled "twin" study with a study period of 48 weeks. All subjects were randomly divided into trial 1 and trial 2 (ie, "twins"). (2) The study was completed in October 2008 to July 2011, screening a total of 1335 cases of asthma in 15 countries, and finally successfully incorporated 912 patients [study group was selected 409 cases (trial 1 group of 211 cases, test 2 (3 cases) were treated with high dose of glucocorticoid (equivalent to budesonide 800 μg / d) and (3) all patients were treated with high dose of glucocorticoid (equivalent to budesonide 800 μg / d) and LABA was treated with tiotropium bromide(136310-93-5) 5 μg /d and the control group received the same placebo with the same device. (4) All patients had no control of asthma at enrollment and FEV1 after bronchodilator % <80%, and these patients had at least 1 severe acute exacerbation of asthma within 1 year prior to enrollment.

Results: (1) The mean baseline FEV1 of the selected subjects was 62% of the predicted value, with an average age of 53 years.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved